Kleptomania is rare enough that DSM based estimates put lifetime prevalence at just 0.1% to 0.3% in the general population, a sharp contrast to the 3.0% of respondents who report compulsive buying. The picture gets even more complicated when you factor in what clinicians look for, like the DSM 5 pattern of rising tension before theft and relief afterward, alongside comorbidity rates that can be striking in real-world samples. Let’s sort through these figures so you can see how often kleptomania is confused with other mental health issues and what the best available data really suggest.
Key Takeaways
- 0.1%–0.3% lifetime prevalence of kleptomania in the general population, according to DSM-based estimates summarized in a clinical review
- 1.0% lifetime prevalence of obsessive-compulsive disorder in the general population (comparator disorder prevalence used to contextualize rarity of kleptomania)
- 50% of people with obsessive-compulsive and related disorders report onset by age 14 in a large epidemiologic synthesis (context: early onset pattern relevant for differential diagnosis)
- 52% of people diagnosed with compulsive stealing/kleptomania in a clinical case-series report comorbid mood and/or anxiety disorders (case-series based; not population prevalence)
- 30% of individuals in a published clinical sample with kleptomania report comorbid substance-use problems (clinical sample proportion)
- Kleptomania has been described in the literature as occurring in patients across the lifespan, with onset often during adolescence or early adulthood in case-based reviews
- In a review of N= series for compulsive stealing, behavioral interventions plus SSRIs are described as leading to decreased theft frequency in reported cases (measurable as 'frequency decrease' outcome direction)
- A commonly cited proportion in U.S. pharmacy benefit analyses is that 10%–20% of prescriptions are involved in adherence or discontinuation issues, which can affect treatment of comorbid conditions (treatment engagement context)
- In randomized controlled trials of SSRIs in obsessive-compulsive related conditions, response rates often fall around 50%–60% (treatment effectiveness benchmark for symptom-aligned interventions)
- A 2023 report estimated global retail shrink at about $120 billion (industry loss estimate context)
- In the U.S., workplace violence is a major cost driver; the BLS estimated 1,000 annual fatalities from workplace homicides across sectors (context for retail security planning)
- Crime prevention spending by U.S. retailers is commonly reported as billions annually; in 2023, loss prevention industry spending exceeded $20 billion globally (industry size estimate context)
- 2.5% of people report engaging in shoplifting behavior at least once in their lifetime (lifetime prevalence of shoplifting behavior in a large community survey).
- 0.23% of people met criteria for kleptomania in a general-population survey reanalysis (DSM-based rare condition estimate).
- 3.0% of respondents reported compulsive buying (a related buying-related compulsivity estimate used in studies of compulsive/impulsive disorders; indicates prevalence of a behavior that is sometimes clinically confused with compulsive stealing).
Kleptomania is rare, affecting about 0.1 to 0.3 percent lifetime, and often co-occurs with anxiety or mood issues.
Related reading
01 · Category
Prevalence Rates9 stats
01
0.1%–0.3% lifetime prevalence of kleptomania in the general population, according to DSM-based estimates summarized in a clinical review
02
1.0% lifetime prevalence of obsessive-compulsive disorder in the general population (comparator disorder prevalence used to contextualize rarity of kleptomania)
03
50% of people with obsessive-compulsive and related disorders report onset by age 14 in a large epidemiologic synthesis (context: early onset pattern relevant for differential diagnosis)
04
1 in 5 adults in the U.S. are estimated to have a mental illness in a given year (context: overall mental illness burden, not kleptomania-specific)
05
2%–3% of adults in the U.S. meet criteria for any obsessive-compulsive spectrum disorder in epidemiologic estimates (context: comparator spectrum prevalence)
06
0.6% lifetime prevalence of specific phobias in adults in a national epidemiologic estimate (context comparator prevalence)
07
0.2% lifetime prevalence of intermittent explosive disorder in a U.S. national survey estimate (context: impulsive behavior disorder prevalence comparator)
08
1.0% lifetime prevalence of posttraumatic stress disorder in a U.S. national survey estimate (context comparator)
09
0.1% lifetime prevalence of anorexia nervosa in U.S. epidemiologic estimates (context: rare psychiatric disorder comparator)
Interpretation
Prevalence Rates Interpretation
Under the prevalence rates framing, kleptomania appears extremely rare at about 0.1% to 0.3% lifetime prevalence, far lower than several common comparator disorders such as obsessive-compulsive disorder at 1.0% and PTSD at 1.0%, underscoring how uncommon it is in the general population.
02 · Category
Clinical Correlates11 stats
01
52% of people diagnosed with compulsive stealing/kleptomania in a clinical case-series report comorbid mood and/or anxiety disorders (case-series based; not population prevalence)
02
30% of individuals in a published clinical sample with kleptomania report comorbid substance-use problems (clinical sample proportion)
03
Kleptomania has been described in the literature as occurring in patients across the lifespan, with onset often during adolescence or early adulthood in case-based reviews
04
30%–60% of OCD patients have symptoms that worsen under stress in longitudinal and cohort studies summarized in a psychiatric review (used as comparator for symptom triggers)
05
Up to 90% of patients with impulse-control disorders can have at least one psychiatric comorbidity in review literature (comorbidity burden context)
06
In a major review of hoarding and related disorders, about 75% of patients report comorbidity with mood and anxiety disorders (comorbidity context for related impulse/compulsive presentations)
07
Across psychiatric inpatient samples, rates of substance-use comorbidity commonly range from ~20% to 40% (used as comparator context for clinical co-occurrence of impulse-related conditions)
08
In a large U.S. psychiatric comorbidity analysis, 47.4% of adults with any mental illness also had a substance-use disorder (comorbidity burden context)
09
60% of adults with mental illness in the U.S. report at least one co-occurring condition (analysis context for multimorbidity burden)
10
DSM-5 describes a rising tension before the act and relief after committing theft for kleptomania (core diagnostic criterion measurable as 'tension-relief' temporal pattern in definition)
11
The ICD-11 draft classification resources note that kleptomania is part of impulse-control disorder groupings used in clinical coding frameworks (classification-based measurable definitional mapping)
Interpretation
Clinical Correlates Interpretation
In clinical samples, kleptomania shows a strong comorbidity pattern with about 52% reporting mood and/or anxiety disorders and around 30% reporting substance use problems, underscoring that the key clinical correlates are widespread and often involve other psychiatric conditions rather than occurring in isolation.
03 · Category
Treatment & Outcomes12 stats
01
In a review of N= series for compulsive stealing, behavioral interventions plus SSRIs are described as leading to decreased theft frequency in reported cases (measurable as 'frequency decrease' outcome direction)
02
A commonly cited proportion in U.S. pharmacy benefit analyses is that 10%–20% of prescriptions are involved in adherence or discontinuation issues, which can affect treatment of comorbid conditions (treatment engagement context)
03
In randomized controlled trials of SSRIs in obsessive-compulsive related conditions, response rates often fall around 50%–60% (treatment effectiveness benchmark for symptom-aligned interventions)
04
In meta-analyses of cognitive-behavioral therapy for OCD, effect sizes are moderate to large (e.g., Hedges g around 0.5–0.8 in pooled analyses), used as a benchmark for CBT effectiveness relevant to impulse-compulsion interventions
05
In a systematic review, N-acetylcysteine showed benefit in compulsive behaviors with clinical trial outcomes improving symptom measures by several points on standardized scales (used as an evidence benchmark for glutamatergic augmentation strategies)
06
Exposure and response prevention (ERP) is identified as an evidence-based therapy for OCD with multiple RCTs supporting efficacy, informing ERP-like approaches for compulsive stealing symptoms
07
In a review of impulse-control disorder treatments, pharmacotherapy (e.g., SSRIs) is reported as showing symptom reduction in multiple case reports and small series, with effect direction consistently favorable in published outcomes
08
A clinical guideline for impulse-control and related disorders emphasizes multimodal care, including psychotherapy and medication when indicated (measurable as 'recommended components' count: 2 components)
09
In a meta-analysis of psychotherapy for anxiety disorders, average effect sizes are in the moderate range (e.g., standardized mean differences ~0.5), providing a benchmark for expected CBT gains
10
In depression treatment meta-analyses, CBT and antidepressants each show measurable reductions on standardized depression scales (benchmark effect sizes often ~0.3–0.5)
11
A systematic review reports that remission rates in OCD typically range around 10%–30% depending on definition and treatment intensity (benchmark for 'remission' outcome)
12
In OCD trials of CBT/ERP, attrition rates often fall in the ~10%–30% range across studies (benchmark for 'dropout' outcome)
Interpretation
Treatment & Outcomes Interpretation
Across Treatment & Outcomes evidence for impulse-compulsion like kleptomania, serotonin-based and therapy approaches appear meaningfully helpful, with RCT symptom response commonly around 50% to 60% and OCD remission often reported at about 10% to 30%, while attrition typically stays near 10% to 30%.
04 · Category
Economic & Industry Impact3 stats
01
A 2023 report estimated global retail shrink at about $120 billion (industry loss estimate context)
02
In the U.S., workplace violence is a major cost driver; the BLS estimated 1,000 annual fatalities from workplace homicides across sectors (context for retail security planning)
03
Crime prevention spending by U.S. retailers is commonly reported as billions annually; in 2023, loss prevention industry spending exceeded $20 billion globally (industry size estimate context)
Interpretation
Economic & Industry Impact Interpretation
From an economic and industry impact perspective, the scale of theft linked losses is reflected in figures like $120 billion in global retail shrink in 2023 and a global loss prevention market topping $20 billion, signaling that retailers are investing billions in prevention as the broader security costs around serious violence remain significant.
More related reading
05 · Category
Prevalence Estimates4 stats
01
2.5% of people report engaging in shoplifting behavior at least once in their lifetime (lifetime prevalence of shoplifting behavior in a large community survey).
02
0.23% of people met criteria for kleptomania in a general-population survey reanalysis (DSM-based rare condition estimate).
03
3.0% of respondents reported compulsive buying (a related buying-related compulsivity estimate used in studies of compulsive/impulsive disorders; indicates prevalence of a behavior that is sometimes clinically confused with compulsive stealing).
04
1.2% of adults in the same international survey reported doing so multiple times (repeat unauthorized-taking behavior).
Interpretation
Prevalence Estimates Interpretation
In prevalence estimates, kleptomania appears rare at about 0.23% in reanalysis, far below the 2.5% lifetime shoplifting reports, suggesting that only a small fraction of unauthorized-taking behaviors translate into the clinical pattern captured by DSM-based kleptomania criteria.
06 · Category
Comorbidity Patterns6 stats
01
34% of people who reported impulsive behavior disorders also reported having a mood or anxiety disorder comorbidity in a large clinical epidemiologic report (comorbidity burden relevant to differentiating kleptomania presentations).
02
47% of adults with any psychiatric disorder reported at least one comorbid substance-use disorder in a nationally representative epidemiologic analysis (general comorbidity magnitude for substance co-occurrence).
03
22% of adults with impulse-control problems reported major depressive disorder comorbidity in a cross-national psychiatric epidemiology study.
04
18% of adults with impulse-control disorders reported anxiety disorders comorbidity in a meta-analytic review of psychiatric comorbidity patterns.
05
29% of clinical cases involving impulse-related behaviors had a substance-use disorder diagnosis in a systematic review of impulse-control and related conditions.
06
36% of patients with hoarding or compulsive hoarding-adjacent presentations had comorbid anxiety or depressive disorders in a large clinical review synthesis.
Interpretation
Comorbidity Patterns Interpretation
Across comorbidity patterns linked to kleptomania-relevant impulse-control presentations, substance use and mood or anxiety disorders frequently travel together, with 47% reporting at least one comorbid substance-use disorder and 34% reporting mood or anxiety comorbidity in large epidemiologic samples.
07 · Category
Treatment Effectiveness4 stats
01
ERP (exposure and response prevention) is supported by meta-analytic evidence for OCD: pooled outcomes show clinically meaningful symptom reduction with ERP compared with control conditions.
02
CBT-based approaches for obsessive-compulsive and related disorders show moderate-to-large standardized effects in pooled analyses, with effect sizes frequently around the 0.5 range (evidence benchmark for compulsive-spectrum therapies).
03
SSRIs are first-line pharmacotherapy for OCD: clinical practice guidance recommends SSRI-class antidepressants as standard medication options.
04
Across randomized trials of glutamatergic augmentation in OCD, response improvements have been observed for N-acetylcysteine in meta-analytic summaries (quantifies benefit as symptom score improvement).
Interpretation
Treatment Effectiveness Interpretation
For treatment effectiveness in kleptomania-related compulsive-spectrum symptoms, meta-analytic evidence suggests ERP and CBT deliver clinically meaningful improvements with pooled effects often around 0.5, while first-line SSRI medication is recommended for OCD and glutamatergic augmentation such as N-acetylcysteine shows additional symptom score gains across randomized trials.
08 · Category
Clinical Definitions3 stats
01
The WHO ICD-11 framework defines a group of disorders characterized by impulse-control difficulties with failure to resist impulses (classification basis used in clinical coding systems).
02
DSM-5 distinguishes kleptomania from stealing motivated by anger, delusions, hallucinations, conduct disorder, or mania (exclusion criteria).
03
DSM-5 lists diagnostic specifiers for obsessive-compulsive related disorders that include severity and course dimensions, enabling standardized reporting of treatment response.
Interpretation
Clinical Definitions Interpretation
In the clinical definitions framing, the key trend across WHO ICD-11 and DSM-5 is that kleptomania is defined primarily by impulse control failure to resist, while DSM-5 also sharply excludes stealing driven by factors like anger, delusions, hallucinations, conduct disorder, or mania, with diagnostic specifiers used to standardize reporting of severity and course.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Marie Larsen. (2026, February 13). Kleptomania Statistics. Gitnux. https://gitnux.org/kleptomania-statistics
MLA
Marie Larsen. "Kleptomania Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/kleptomania-statistics.
Chicago
Marie Larsen. 2026. "Kleptomania Statistics." Gitnux. https://gitnux.org/kleptomania-statistics.
Sources & references
52 datasets cited across this report · attribution is report-level
+30 additional datasets cited (not shown individually)